about
Molecular signaling involving intrinsically disordered proteins in prostate cancerRole of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular CarcinomaSuppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.Biological Processes Discovered by High-Throughput Sequencing.Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.Androgen receptor antagonists in castration-resistant prostate cancer.Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancerPalmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP.N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor.STAMP2 increases oxidative stress and is critical for prostate cancer.Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Integrative molecular profiling of routine clinical prostate cancer specimens.The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.Castration-resistant prostate cancer: potential targets and therapies.Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.Physiopathological aspects of the Wnt/β-catenin signaling pathway in the male reproductive systemMolecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.Agonists of luteinizing hormone-releasing hormone in prostate cancer.Disruption of prostate epithelial differentiation pathways and prostate cancer development.Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.Mini-review: androgen receptor phosphorylation in prostate cancerPharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.Intracrine androgen biosynthesis in renal cell carcinoma.Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.Bisbibenzyls, novel proteasome inhibitors, suppress androgen receptor transcriptional activity and expression accompanied by activation of autophagy in prostate cancer LNCaP cells.Divergent androgen regulation of unfolded protein response pathways drives prostate cancer.The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.Prostate cancer diagnosis using epigenetic biomarkers, 3D high-content imaging and probabilistic cell-by-cell classifiers.Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP.β4-integrin-mediated cytotoxic activity of AexU in human prostate cancer PC3 cells.
P2860
Q26747089-5ABC99B7-ABEF-4A5A-B58F-68B24247FF86Q26778413-2BD30413-1873-470D-89DB-FA8B2262AA57Q30008838-5FE6184B-9B09-4142-B226-44BBC561AAAAQ30277646-7CB0D07E-2BC5-42C1-B321-575B18C32FB7Q34194760-4F8A1884-08B7-4167-9FF9-F4DB8CBA626FQ34323656-1F373655-B49D-4CBA-A2D3-3561832A4C24Q34364815-EB39D4DD-E3B2-4986-BDC3-D1DAEB24928BQ34429968-BC94CDEB-DAC2-48CF-9504-C8ECEB45744BQ34749943-31DA418D-60F7-4DF9-805F-ED3D7CEAEA43Q35192455-9EA51763-051E-46AA-8A62-9EC466DB2EFBQ35423247-7D12EEF8-D762-4681-9C9E-305D0B1D197EQ35555483-9CE5114E-A53C-4D0B-BD5B-FEBF4A757368Q35892022-DC18AC43-1819-4909-88BE-7DEB0EC22D3EQ35963298-FB102781-1705-4938-8A1F-38788F7CC014Q36098127-FBFBAA31-31D0-4BB0-8F31-BA47C88B45D9Q36196682-116849DB-A6CE-40D0-A083-DBA05BFD666DQ36685517-59D415FA-4702-405B-ADA4-20CAD863E18DQ36738996-6515C1DD-028F-401F-8123-594CA48FBA13Q36815379-4DA7A305-D93F-4240-A907-2F59E872BB23Q37010879-7246D308-2C62-4765-B436-CB87BADC6C90Q38039759-3EFD7009-5D6F-4DE6-99BA-FD8B0714643AQ38132229-9C9F8618-A23D-4097-8D57-442E4A266C59Q38160495-457D8E8F-BD62-44F6-9AA1-60FC2417BA88Q38165773-99DBF462-69B0-4197-8AA5-37961077ABCDQ38265565-AC24D278-A390-40E5-AB0A-67045A7F7FB1Q38455793-C0DB8C06-6347-41DE-B730-0449F9175AFFQ38714201-759D7636-7FED-461C-97C8-8E834E962195Q38785291-F66FB700-FB2E-4164-B532-F9DA5750E450Q38870314-E13BA03A-7631-4CDB-B961-032E2DDA5AF2Q38888506-05BF3F20-A05D-4653-9576-AA7695EE809EQ38964546-7FC98DDF-1A0F-4B8F-B3B3-56E694B64AE7Q38994718-20602D08-C83E-43C0-8E8F-674734003509Q39181062-B173109C-C0C8-4CD0-8156-FD366842BC2DQ39251637-514702B0-2B9E-4026-8D42-9F35F8EE8BD8Q40395168-A5D61CF2-C3E3-4CA8-98BB-E9CE07437BB0Q40452694-8BBC21BA-27D7-48C9-A2A0-E44B21BEEFBDQ41342281-CB4A6791-BB3B-45D9-8762-CB817175D949Q42019892-22472BFD-1B65-4E3C-9748-DE198795415CQ42562947-739F58D0-62FD-472F-AC62-14016085F709Q42926749-CB2CCD36-266E-47BD-8A8B-F03582211509
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The androgen/androgen receptor axis in prostate cancer.
@en
The androgen/androgen receptor axis in prostate cancer.
@nl
type
label
The androgen/androgen receptor axis in prostate cancer.
@en
The androgen/androgen receptor axis in prostate cancer.
@nl
prefLabel
The androgen/androgen receptor axis in prostate cancer.
@en
The androgen/androgen receptor axis in prostate cancer.
@nl
P2860
P1476
The androgen/androgen receptor axis in prostate cancer.
@en
P2093
Eric G Bluemn
Peter S Nelson
P2860
P304
P356
10.1097/CCO.0B013E32835105B3
P577
2012-05-01T00:00:00Z